Nature Journal: Molecular Gel Development, Birth of a 'New Approach'Reprinted: Medical Magic CubeMolecular glue is an important protein degrading agent that can achieve dual functions of recruiting target proteins and E3 ligases. Due to its small molecular weight, it has advantages in drug formation.However, currently most molecular gels are discovered by chance. The existing rational design strategies are mostly obtained through medicinal chemistry methods, optimizing the structure and

The pan RAS inhibitor has positive results in the treatment of pancreatic cancer in phase I, and will enter phase III clinicalReprinted: Medical Magic CubeOn July 15, Revolution Medicines said in a report released to investors that its RAS (ON) multi selective inhibitor RMC-6236 would enter the phase III trial of pancreatic cancer after the encouraging results of phase I study. The latest results show that the tumor shrinkage rate of pancreatic ductal carcinoma (PDAC) patients is as high as 27%.

Discovery and optimization of potent and novel GPR132 (G2A) agonists by drug crossing Cyber analysisReprinted: ZhihuG protein coupled receptor GPR132, also known as G2A. In 1998, Ludwig et al. proposed the concept of proton sensitive GPCRs in 2003 and classified four orphan receptors of the AGPCR class: GPR4, TDAG8 (GPR65), OGR1 (GPR68), and G2A into this family. The role of proton sensing GPCRs was initially believed to be sensing tissue damage, inflammation, or tumor growth caused by a decreas

45% of patients lose 20% weight! Roche GLP-1/GIP agonist is comingReprinted: Pharmaceutical Intelligence NewsOn July 15th, Roche released phase Ib clinical data of its GLP-1/GIP small molecule agonist CT-388, which showed that higher doses had not yet reached peak weight loss at 6 months.A summary to be published at the annual meeting of the European diabetes Research Association in Madrid in September shows that the weight loss effect of CT-388 in 24 weeks has not stabilized, which means that i

44 innovative drugs approved for market launch (list attached)Date: August 1, 2024 Author: Yaozhi News [Reprinted] Source: Yaozhi NewsReprinted: Pharmaceutical Intelligence NewsRecently, the leading CRO company in China, WuXi AppTec, released an overview of the highlights of China's innovative drug field in the first half of 2024 (hereinafter referred to as the Overview), which sorted out the highlights of China's innovative drug field in the first half of 2024.According to the Overview,

Reprinted: ZhihuWith the development of technology, there are increasingly more available drug targets for cancer. The target KRAS, which was previously considered untreatable, has also been approved for market and is currently a hot research and development topic in different mutants and indications. This article will start from the biological function and protein structure of KRAS, and explain the difficulties in drug development, research breakthroughs, and potential resistance mechanisms of